← Leaderboards
Satu Mustjoki
Dana-Farber Cancer Inst
$597,375
Attributed
$1,194,750
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $406K · FY2023–25$500K$375K$250K$125K$0
'23
'24
'25
Funding mix
By agency
NIH$1,194,750 · 1
By mechanism
R01$1,194,750 · 1
Top collaborators
- Constantine S. Mitsiades4 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Benjamin Levine Ebert$26,802,844
- Alex Kentsis$10,070,317
- Richard M Stone$3,984,410
- Herve Avet Loiseau$3,475,894
- Donald W. Kufe$50,160,456
Others in their field
Other Rising Stars on “Disease Outcome”
- Rebecca Montalvan · Westat, Inc.$86,600,000
- Mari Ostendorf · University Of Washington$51,931,230
- Suma Babu · Massachusetts General Hospital$34,837,233
- Sabrina Paganoni · Massachusetts General Hospital$34,837,233
- Supriya Menezes · The Emmes Company, Llc$25,277,032
- Jinsy Andrews · Columbia University Health Sciences$21,294,649
Research focus
Disease OutcomeAcute Myelocytic LeukemiaBiologyApoptoticBiochemicalCancer TherapyCell CommunicationCell CompartmentationCell LineCancer BurdenCancer CellCessation Of LifeCharacteristicsChemotherapyClustered Regularly Interspaced Short Palindromic RepeatsCollaborationsComplexCytotoxicCytotoxic AgentCytotoxic ChemotherapyCytotoxic T-LymphocytesCellsDiapauseDisease Remission
Grant awards (4)
Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies$393,853
R01 · FY2025 · CA
Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies$9,250
R01 · FY2025 · CA
Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies$385,609
R01 · FY2024 · CA
Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies$406,038
R01 · FY2023 · CA